IMMUNOCORE HLDGS ADS/1 (6YG) — Tangible Net Worth Ratio
IMMUNOCORE HLDGS ADS/1 (6YG) has a Tangible Net Worth Ratio of 100.0% as of June 2026. This metric is calculated by deducting intangible assets (€0.00) from net assets (€419.80 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore 6YG net assets growth trend to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
IMMUNOCORE HLDGS ADS/1 Tangible Net Worth Ratio (2022–2025)
This chart shows how IMMUNOCORE HLDGS ADS/1's Tangible Net Worth Ratio has changed across 4 annual periods from 2022 to 2025. As of June 2026, the ratio stands at 100.0%, reflecting net assets of €419.80 Million with intangible assets of €0.00 EUR. For live market cap and overall valuation, see 6YG company net worth.
Annual Tangible Net Worth Ratio for IMMUNOCORE HLDGS ADS/1 (2022–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for IMMUNOCORE HLDGS ADS/1 from 2022 to 2025, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore IMMUNOCORE HLDGS ADS/1 capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 100.0% | €381.03 Million | €0.00 | €1.07 Billion | ▲ +0.0 pp |
| 2024 | 100.0% | €360.72 Million | €0.00 | €1.01 Billion | ▲ +0.0 pp |
| 2023 | 100.0% | €368.84 Million | €0.00 | €597.00 Million | ▲ +0.0 pp |
| 2022 | 100.0% | €338.90 Million | €0.00 | €526.76 Million | — |